Skip to main content
Log in

Fortgeschrittenes Ovarialkarzinom und BRCA-Mutation

Erhaltungstherapie mit Olaparib führt zu signifikant verlängertem PFS

  • journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

1

Literatur

  1. Moore K et al. N Engl J Med. 2018;379(26):2495–505

    Article  CAS  Google Scholar 

  2. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

  3. Ledermann JA et al. Ann Oncol. 2013;24 Suppl 6:vi24–32

    PubMed  Google Scholar 

  4. Burger RA et al. N Engl J Med. 2011;365(26):2473–83

    Article  CAS  Google Scholar 

  5. Perren TJ et al. N Engl J Med. 2011;365(26):2484–96

    Article  CAS  Google Scholar 

Literatur

  • Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26): 2495–505

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Eichbaum.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eichbaum, M., Eichbaum, C. Erhaltungstherapie mit Olaparib führt zu signifikant verlängertem PFS. Info Onkol. 22, 21–22 (2019). https://doi.org/10.1007/s15004-019-6424-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6424-1

Navigation